Supplemental Table S4 from Phase 2 Study of Zilovertamab Vedotin in Participants with Metastatic Solid Tumors

Key Points

• The results highlight the efficacy of zilovertamab vedotin in treating patients with metastatic solid tumors.
• Using RECIST version 1.1, the study provides a detailed investigator assessment of treatment outcomes.
• Participants in the study showcased a response to the therapy, suggesting a promising avenue for future treatments.
• The findings may support ongoing clinical development of zilovertamab vedotin for difficult-to-treat tumors.